| 7.56 0.22 (3%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.65  |
1-year : | 11.15 |
| Resists | First : | 8.27 |
Second : | 9.55 |
| Pivot price | 7.65  |
|||
| Supports | First : | 6.19 | Second : | 5.15 |
| MAs | MA(5) : | 7.21 |
MA(20) : | 7.81 |
| MA(100) : | 10.62 |
MA(250) : | 11.96 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 35.3 |
D(3) : | 30.5 |
| RSI | RSI(14): 43 |
|||
| 52-week | High : | 17.74 | Low : | 5.93 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DRIO ] has closed above bottom band by 45.9%. Bollinger Bands are 25.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.77 - 7.8 | 7.8 - 7.82 |
| Low: | 7.12 - 7.15 | 7.15 - 7.18 |
| Close: | 7.51 - 7.55 | 7.55 - 7.6 |
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Mon, 13 Apr 2026
DarioHealth (DRIO) director reports owning 4,500 common shares - Stock Titan
Mon, 13 Apr 2026
John R. Palumbo appointed to DarioHealth board - TradingView — Track All Markets
Mon, 13 Apr 2026
Veteran executive joins DarioHealth (NASDAQ: DRIO) board to drive scaling - Stock Titan
Mon, 13 Apr 2026
DarioHealth taps 40-year healthcare veteran to help scale partnerships - Stock Titan
Mon, 30 Mar 2026
DarioHealth (NASDAQ: DRIO) launches $20M at-the-market stock program - Stock Titan
Thu, 19 Mar 2026
DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 21.4 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 67 (K) |
| EPS | -10.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.84 |
| Profit Margin | -186.6 % |
| Operating Margin | -163.7 % |
| Return on Assets (ttm) | -20.1 % |
| Return on Equity (ttm) | -59.7 % |
| Qtrly Rev. Growth | -31.3 % |
| Gross Profit (p.s.) | 1.96 |
| Sales Per Share | 3.06 |
| EBITDA (p.s.) | -4.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.75 |
| PEG Ratio | 0 |
| Price to Book value | 0.76 |
| Price to Sales | 2.46 |
| Price to Cash Flow | -2.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|